Lecap Asset Management Ltd. Trims Stake in Danaher Corporation (NYSE:DHR)

Lecap Asset Management Ltd. trimmed its stake in Danaher Corporation (NYSE:DHR - Free Report) by 88.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,428 shares of the conglomerate's stock after selling 11,165 shares during the period. Lecap Asset Management Ltd.'s holdings in Danaher were worth $293,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Fortis Capital Advisors LLC boosted its holdings in Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares during the last quarter. Fayez Sarofim & Co increased its position in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after purchasing an additional 50 shares during the last quarter. Coastal Bridge Advisors LLC increased its position in shares of Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after purchasing an additional 50 shares during the last quarter. Perennial Investment Advisors LLC increased its position in shares of Danaher by 2.2% during the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after purchasing an additional 51 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its stake in shares of Danaher by 3.1% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after acquiring an additional 52 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DHR. The Goldman Sachs Group reduced their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Bank of America dropped their price objective on Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Guggenheim reissued a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Leerink Partners boosted their price target on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $248.61.

Danaher Price Performance

NYSE DHR traded down $3.26 during trading hours on Friday, reaching $198.20. 5,619,393 shares of the stock traded hands, compared to its average volume of 3,505,685. The stock has a 50 day simple moving average of $194.61 and a two-hundred day simple moving average of $208.77. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market cap of $141.84 billion, a price-to-earnings ratio of 38.48, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's dividend payout ratio is currently 24.85%.

Insider Transactions at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.